Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financials
$16.52−0.75%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M | $45.6M | $36.6M | $26.9M | $17.2M |
| Gross profit | $42.3M | $36.8M | $61.6M | $45.0M | $36.7M | $31.0M | $26.1M | $20.8M | $13.6M |
| Gross margin | 66.9% | 63.8% | 72.9% | 59.4% | 53.4% | 68.0% | 71.2% | 77.2% | 78.8% |
| Operating income | -$70.2M | -$110.4M | -$142.3M | -$203.6M | -$188.5M | -$94.3M | -$110.8M | -$120.0M | -$89.8M |
| Net income | -$1.9M | -$55.9M | -$68.7M | -$94.6M | -$64.7M | -$46.5M | -$40.0M | -$84.1M | -$66.9M |
| Net margin | −3.0% | −96.9% | −81.3% | −124.9% | −94.1% | −102.0% | −109.1% | −313.0% | −387.8% |
| Diluted EPS | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-11.85 | $-9.75 | $-10.95 | $-29.10 | $-24.15 |
| EBITDA | -$65.6M | -$102.0M | -$128.9M | -$196.2M | -$166.1M | -$86.1M | -$32.5M | -$117.9M | -$88.5M |
| Operating cash flow | -$65.8M | -$80.2M | -$128.2M | -$179.4M | -$116.5M | -$83.7M | -$95.0M | -$98.8M | -$85.7M |
| Free cash flow | -$65.8M | -$80.2M | -$128.3M | -$182.5M | -$121.1M | -$85.6M | -$97.3M | -$105.9M | -$86.4M |
| Diluted shares | 27.9M | 20.8M | 8.1M | 5.9M | 5.4M | 4.8M | 3.6M | 2.9M | 2.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M | $233.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $52.4M | $58.0M | $60.9M | $105.4M | $43.7M | $51.7M |
| Total assets | $185.5M | $144.2M | $167.5M | $294.3M | $396.5M | $333.4M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M | $136.4M |
| Shareholders' equity | $62.2M | -$1.6M | $1.6M | $50.0M | $225.9M | $197.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology